Brief: Supernus Announces Topline Results From Phase 2B Study In Adults With Treatment Resistant Depression
18/02/2025 22:42
Feb 18 (Reuters) - Supernus Pharmaceuticals Inc
SUPN.O :
* SUPERNUS ANNOUNCES TOPLINE RESULTS FROM PHASE 2B STUDY IN
ADULTS
WITH TREATMENT RESISTANT DEPRESSION
* SUPERNUS PHARMACEUTICALS INC - PHASE 2B STUDY OF SPN-820
IN TRD
FAILS PRIMARY ENDPOINT
* SUPERNUS PHARMACEUTICALS INC - SPN-820 SAFETY PROFILE
CONSISTENT
WITH PREVIOUS TRIALS
Source text: ID:nGNX7YJMG2
Further company coverage: SUPN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Supernus Pharmaceuticals
See all newsHuron Consulting poised to hit fresh record ahead of S&P SmallCap addition
Brief: S&P Dow Jones Indices Msg Rangers And Huron Consulting Group Set To Join S&P Smallcap 600
Brief: Supernus Pharmaceuticals Says FDA Grants Seven Years Orphan-Drug Exclusivity For Onapgo
Supernus Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE -Micron Technology, Ares Management, Boeing